跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 59,334 条关于
“Alk Positive Inc.”
全部
59,334
临床试验
25,419
药物
2,187
机构
6,234
资讯
25,494
2个月前
Targeted Therapies Transform Stage 4 Lung Cancer from Death Sentence to Chronic Condition
2年前
Pfizer's Crizotinib Explores New Frontier in HER2-Negative Breast Cancer Treatment
去年
Neoadjuvant Immunotherapy Emerges as Promising Strategy for Early-Stage NSCLC Treatment
去年
Genprex and University of Michigan Partner to Study Reqorsa® Gene Therapy in ALK+ Lung Cancer
去年
Lorlatinib Shows Impressive 5-Year PFS Results in ALK-Positive Advanced NSCLC
4个月前
Xcovery Partners with EVERSANA to Expand Commercial Launch of ALK-Positive NSCLC Drug Ensacove
去年
ALNEO Trial Demonstrates Promising Perioperative Alectinib Activity in Stage III ALK-Positive NSCLC
去年
Alectinib Plus Bevacizumab Shows Promising Results in First-Line Treatment of ALK-Positive NSCLC
4个月前
Chugai's Alecensa Receives World's First Tumor-Agnostic Approval for ALK Fusion-Positive Solid Tumors
去年
Adjuvant Crizotinib Fails to Improve Disease-Free Survival in Early-Stage ALK-Positive NSCLC
第 1 页,共 2550 页
上一页
下一页